Deflazit 18 Tablet
Deflazacort
18 mg
Incepta Pharmaceuticals Ltd.
| Pack size | 20's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 20.00 AED |
Available as:
Indications
Deflazit 18 Tablet is used for:
Allergic and inflammatory disorders, Duchenne muscular dystrophy
Adult Dose
Oral
Allergic and inflammatory disorders
Adult:
Usual maintenance 3–18 mg daily (acute disorders, initially up to 120 mg daily).
Rheumatoid arthritis: 3-18 mg/day
Bronchial asthma: 48-72 mg/day.
Duchenne Muscular Dystrophy
Indicated for Duchenne muscular dystrophy (DMD)
0.9 mg/kg/day once-daily
Child Dose
Oral
Allergic and inflammatory disorders
Child 1 month–11 years: 0.25–1.5 mg/kg daily or on alternate days; up to 2.4 mg/kg (max.120 mg) daily in emergency situations.
Child 12–17 years: 3–18 mg daily or on alternate days; up to 2.4 mg/kg (max. 120 mg) daily in emergency situations.
Renal Dose
Renal impairment
Mild, moderate, or severe: No dose adjustment required
Administration
May take with or without food
Contra Indications
Systemic infection; live virus vaccines in those receiving immunosuppressive doses.
Precautions
Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia can occur;
Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal; Signs and symptoms of infection may be masked (5.2)
Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and sodium, and for decreased potassium levels Gastrointestinal Perforation: Increased risk in patients with certain GI disorders; Signs and symptoms may be masked
Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis
Effects on Bones: Monitor for decreases in bone mineral density with chronic use of Deflazacort
Ophthalmic Effects: May include cataracts, infections, and glaucoma;
Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live attenuated or live vaccines at least 4 to 6 weeks prior to starting Deflazacort
Serious Skin Rashes: Discontinue at the first sign of rash, unless the rashes clearly not drug-related
Monitor intraocular pressure if Deflazacort is continued for more than 6 weeks
Monitor patients for Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia with chronic use of Deflazacort
Pregnancy-Lactation
Pregnancy
Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism
Lactation
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Moderate or strong CYP3A4 inhibitors: Give one-third of the recommended dosage of Deflazacort
Avoid use of moderate or strong CYP3A4 inducers with Deflazacort, as they may reduce efficacy
Contraindicated (1)
mifepristone
Adverse Effects
Side effects of Deflazacort :
GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.
Mechanism of Action
Deflazacort, derived from prednisolone, is a corticosteroid with mainly glucocorticoid activity. An anti-inflammatory dose of 6 mg deflazacort is equiv to 5 mg prednisolone.
Note
Deflazit 18 18 mg Tablet manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Deflazacort. Deflazit 18 is availble in Bangladesh.
Farmaco BD drug index information on Deflazit 18 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.